SOLICITATION NOTICE
Q -- Laboratory Testing Services for Circulating Inflammation Markers and Prospective Risk of Gastric Cancer related to the “Helicobacter pylori Genome Project”
- Notice Date
- 8/26/2016
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP62680-76
- Archive Date
- 9/10/2016
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address : Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description: National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Infections and Immunoepidemiology Branch (IIB), plans to procure on a sole source basis the laboratory services for extraction and analyses from Vanderbilt University School of Medicine, 2215B Garland Ave. MRB4, Nashville, TN 37232. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 621511 and the business size standard is $32.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price, Indefinite Delivery Indefinite Quantity (IDIQ) type contract. The period of performance of the IDIQ contract is twenty-four (24) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world. The IIB's research mission is to discover infectious causes of cancer, to elucidate the determinants of malignancy for established oncogenic infections, to uncover novel infection-cancer associations, and to clarify how alterations in immunity and inflammation relate to cancer risk. IIB investigators collaborate with researchers from a variety of disciplines in the U.S. and abroad. In addition to epidemiologic and clinical data, many IIB field studies include an extensive biological specimen collection component that allows for careful molecular testing to better define both exposures and outcomes of interest. Helicobacter pylori, a Gram-negative bacterium associated with a spectrum of benign and malignant gastric conditions, is one of the most genetically variable pathogens. Variations in a few genes have been associated with risk of inflammation and carcinogenesis, but to date no systematic study has evaluated the entire bacterial genome. We propose a multicountry study to establish and analyze an informative international collection of H. pylori clinical isolates from residents of defined geographic areas. Molecular characterization will be conducted at the NCI's Frederick National Laboratory for Cancer Research. Our hypothesis is that genetic and epigenetic variations in H. pylori strains among chronically infected individuals may affect risk of progression to gastric cancer. Findings from this study may help to characterize the differential virulence among H. pylori isolates and suggest predictive biomarkers for early diagnosis of cancer. The bacterial isolates and databases from this study will also provide a foundation for further elucidation of H. pylori pathogenesis. The specific aims of this project are: 1. To characterize the spectrum of genomic and epigenomic variations of benign strains of H. pylori based on isolates from chronically infected individuals 2. To identify molecular features that may contribute to pathologic effects by comparing the profile of benign infection to corresponding spectra of isolates from individuals with gastric cancer and premalignant lesions 3. To establish a resource repository of multidimensional data and well-characterized strains for utilization by the scientific community Contractor shall perform the following tasks: • Task #1: Analysis of existing H. pylori isolates: expand (7 Petri plates), extract DNA (2 plates separately) and store (5 plates in separate vials). • Task #2: Analysis of existing H. pylori pools: culture, isolate 1 colony, expand (7 Petri plates), extract DNA (2 plates separately) and store (5 plates in separate vials). • Task #3: Analysis of successful patient biopsies or resections: culture, store 3 pooled vials, isolate 1 colony, expand (7 Petri plates), extract DNA (2 plates separately) and store (5 plates in separate vials). • Task #4: Analysis of unsuccessful patient biopsies or resections: attempted culture. A. CONTRACTOR QUALIFICATIONS The contractor needs to be proficient in culturing H. pylori, maintenance and preparing stocks of bacteria, and DNA extraction as demonstrated by reputation in the field, scientific reports or other evidence of appropriate knowledge and capacity. B. REPORTING AND/OR DELIVERABLES The contractor will provide the following: • DNA samples in appropriate quantity and quality, as discussed with the NCI Technical Point of Contact, for sequencing by PacBio • Maintain a repository of bacterial isolates and provide information about availability through a DCEG inventory system (e.g., BSI), as discussed with the NCI Technical Point of Contact. C. GOVERNMENT RESPONSIBILITIES The Government will be responsible for coordinating of transfer of specimens and data under code. Also, the Government will provide access and training for the selected inventory system. D. PERFORMANCE PERIOD The period of performance will be a twenty-four (24) months from initiation of the IDIQ contract. E. INSPECTION AND ACCEPTANCE The quantity and quality of the deliverables defined in section D will be evaluated prior to acceptance, and subsequently will be accepted within 30 days of receipt. F. PAYMENT The number of samples will be indefinite delivery indefinite quantity (IDIQ). The minimum quantity is two (2) samples for Task Area #1, the minimum quantity is two (2) samples for Task Area #2, the minimum quantity is two (2) samples for Task Area #3, the minimum quantity is two (2) samples for Task Area #4, and the maximum quantity is two-hundred (200) samples for Task Area #1, the maximum quantity is four-hundred (400) samples for Task Area #2, the maximum quantity is two-hundred (200) samples for Task Area #3, and the maximum quantity is two-hundred (200) samples for Task Area #4 during the Period of Performance of twenty-four (24) months. Payment will be made in arrears after receipt and acceptance of requested tasks. This laboratory testing service is provided by the Vanderbilt University School of Medicine. The proposed source is the only known laboratory that can perform all the studies required in the SOW with sufficient capacity and equivalent success rates in working with this type of bacterial pathogen. H. pylori is notoriously difficult to recover from gastric tissue and successfully culture. Dr. Richard M. Peek's Laboratory at Vanderbilt University is nationally and internationally recognized for their expertise in recovering viable H. pylori from human specimens and archived bacterial pools. The source's procedures are both sensitive and specific, and are imperative for the integrity and continuity of the study. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 5:00PM EDT, on Sept. 9, 2016. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02CP62680-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP62680-76/listing.html)
- Record
- SN04242953-W 20160828/160826234759-98ddd1b459cca70d56637120a23c2e37 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |